Join StageBio at the 43rd STP Symposium, June 16-19 in Baltimore. Explore innovative therapeutics and attend our CE course on immunotoxicology with Dr. Papenfuss.

StageBio is excited to participate in and present at the 43rd Annual Society of Toxicologic Pathology (STP) Symposium. This year’s theme, “Innovative Therapeutics: Biology, Toxicologic Pathology and Regulatory Perspectives,” is particularly relevant and eagerly anticipated by our team. We look forward to engaging with our colleagues in sessions covering topics such immunotoxicology, AAV and RNA - based therapies, protein degraders, adoptive cell therapies, AI in the workplace and more. 

During the Symposium, attendees can expect to attend keynote sessions, poster presentations, networking time and more. This event takes place June 16-19 in Baltimore, Maryland.

Be sure and attend our Continuing Education Course on June 16 from 8:00 am - 12:00 pm, Immunotoxicology from a Pathology Perspective. Did you know the field of immunotoxicology originated in the early 1970s? This course will cover how immunotoxicology has evolved, as well as equip pathologists with a deeper understanding of key components to consider, including factors to consider in adversity determination, relevant toxicologic species and translational aspects relating to the immune system, and more. This session is co-chaired by Tracey L. Papenfuss, DVM, MS, PhD, DACVP, StageBio, and Daniel Weinstock, DVM, PhD, DACVP, Independent Consultant. Senior Pathologist Dr. Papenfuss will present, “The Changing Landscape of Immune System Evaluation: From Immunotoxicology and How to Navigate in the Brave New Work of Immunotherapies” during this course. This will be held in room CE1. 

If you would like to connect with StageBio during STP, contact our team here, and we look forward to seeing you soon!  

About StageBio

StageBio is a leading provider of GLP-compliant necropsy, histology, pathology, and specimen archiving and biorepository services for the biopharmaceutical, medical device, academic, and contract research industries. The company operates four GLP laboratories as well as three GLP specimen archiving facilities in the U.S., along with one GLP laboratory in Europe. StageBio will continue to make investments in facility and technology infrastructure to meet the growing demand for high-quality histopathology services globally. StageBio has a team of 30+ board-certified veterinary pathologists and more than 100 laboratory technicians on staff supporting our unified commitment to quality, scientific integrity, and client satisfaction. Learn more at stagebio.com.